Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Oncternal Therapeutics

09/03/2023 21:41

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
December. The mean expectation of six analysts for the quarter
was for a loss of 21 cents per share.
    * Revenue fell 69.2% to $171.00 thousand from a year ago;
analysts
expected $331.50 thousand. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 2% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Oncternal Therapeutics Inc shares had fallen by 10.9% this
quarter.
    * The company reported a quarterly loss of $11.4 million.
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $6.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 9 at 09:41 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.21          -0.20          Beat
 Sep. 30 2022      -0.24          -0.21          Beat
 Jun. 30 2022      -0.23          -0.23          Met
 Mar. 31 2022      -0.20          -0.20          Met